Banamine for Horses and Cattle | On Sale | EntirelyPets Rx
Licensed U.S. Pet Pharmacy | Verified Pharmacy
Mobile Menu
Search Submit
Live Chat My Account
View Cart 0
  • Product ImageProduct Image

Banamine for Horses and Cattle

Item#
FREE SHIPPING Over $59! * Pet Food & Other Exclusions
1. Select type:
QTY:-+

Price too low to show

Add to cart to see low price
RX
  1. We'll ask for your vet's info during check out.
  2. We'll verify your prescription and ship your order!
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
Recurring Saings in EprxAUTOSHIP & SAVE[Details]
$22.95Reg $29.99
$54.85Reg $66.99
$22.95Reg $29.99
$33.99Reg $44.99
  • Description
  • Ingredients
  • Directions
  • FAQ
  • Reviews

Description

Banamine Injectable Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.

Key Benefits

  • Bovine and equine drug
  • Flunixin meglumine
  • Relives pain and inflammation
  • Controls BRD in cattle

Horse: Banamine Injectable Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.

Cattle: Banamine Injectable Solution is indicated for the control of pyrexia associated with bovine respiratory disease and endotoxemia and acute bovine mastitis. Banamine Injectable Solution is also indicated for the control of inflammation in endotoxemia.

  • The original - Banamine brand of flunixin meglumine is the pioneer non-steroidal anti-inflammatory drug (NSAID) approved for horses in the United States
  • Trusted - Banamine is a consistent and trusted NSAID for horses with inflammation and pain associated with musculoskeletal injuries
  • Quick control - Banamine Solution quickly controls inflammatory responses with an onset of activity within two hours of administration
  • Backed by Merck Animal Health - Included in the trusted pain management portfolio from Merck Animal Health that also includes DOLOREX® (butorphanol tartrate)

How It Works

Flunixin meglumine, the main ingredient in Banamine Injectable Solution (flunixin meglumine), is used to relieve pain and inflammation in horses and cattle and for its antipyretic properties. Banamine injectable is a part of the non-steroidal anti-inflammatory class of drugs (NSAIDs).

Indications:

Banamine Injectable Solution is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. It is also recommended for the alleviation of visceral pain associated with colic in the horse.

Ingredients

Each ml of Banamine® Injectable contains flunixin meglumine equivalent to 50 mg flunixin, 0.1 mg edetate disodium, 2.5 mg sodium formaldehyde sulfoxylate, 4.0 mg diethanolamine, 207.2 mg propylene glycol; 5.0 mg phenol as preservative, hydrochloric acid, water for injection qs.

Directions

Horse: The recommended dose for musculoskeletal disorders is 0.5 mg per pound (1 mL/100 lbs) of body weight once daily. Treatment may be given by intravenous injection and repeated for up to 5 days. Studies show onset of activity is within 2 hours. Peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours.

The recommended dose for the alleviation of pain associated with equine colic is 0.5 mg per pound of body weight. Intravenous administration is recommended for prompt relief. Clinical studies show pain is alleviated in less than 15 minutes in many cases. Treatment may be repeated when signs of colic recur. During clinical studies approximately 10% of the horses required one or two additional treatments. The cause of colic should be determined and treated with concomitant therapy.

Not for use in horses intended for human consumption. The effect of Banamine Injectable on pregnancy has not been determined.

Cattle: The recommended dose for control of pyrexia associated with bovine respiratory disease and endotoxemia and control of inflammation in endotoxemia, is 1.1 to 2.2 mg/kg (0.5 to 1 mg/lb; 1 to 2 mL per 100 lbs) of body weight given by slow intravenous administration either once a day as a single dose or divided into two doses administered at 12-hour intervals for up to 3 days. The total daily dose should not exceed 2.2 mg/kg (1.0 mg/lb) of body weight. Avoid rapid intravenous administration of the drug.

The recommended dose for acute bovine mastitis is 2.2 mg/kg (1 mg/lb; 2mL per 100 lbs) of body weight given once by intravenous administration.

Contraindications

Horse: There are no known contraindications to this drug when used as directed. Intra-arterial injection should be avoided. Horses inadvertently injected intra-arterially can show adverse reactions. Signs can be ataxia, incoordination, hyperventilation, hysteria, and muscle weakness. Signs are transient and disappear without antidotal medication within a few minutes. Do not use in horses showing hypersensitivity to flunixin meglumine.

Cattle: There are no known contraindications to this drug in cattle when used as directed. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration are suspected.

Residue Warnings:

Cattle must not be slaughtered for human consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Not for use in dry dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Not for use in horses intended for food.

Precautions

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal and renal toxicity. Sensitivity to drug-associated adverse effects varies with the individual patient. Patients at greatest risk for renal toxicity are those that are dehydrated, on concomitant diuretic therapy, or those with renal, cardiovascular, and/or hepatic dysfunction. Since many NSAIDs possess the potential to induce gastrointestinal ulceration, concomitant use of Banamine Injectable Solution with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided or closely monitored.

Horse: The effect of Banamine Injectable Solution on pregnancy has not been determined. Studies to determine activity of Banamine Injectable Solution when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy

Cattle: Do not use in bulls intended for breeding, as reproductive effects of Banamine Injectable Solution in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. The effects of flunixin on imminent parturition have not been evaluated in a controlled study. NSAIDs are known to have the potential to delay parturition through a tocolytic effect. Do not exceed the recommended dose.

Safety:

Horse: A 3-fold intramuscular dose of 1.5 mg/lb of body weight daily for 10 consecutive days was safe. No changes were observed in hematology, serum chemistry, or urinalysis values. Intravenous dosages of 0.5 mg/lb daily for 15 days; 1.5 mg/lb daily for 10 days; and 2.5 mg/lb daily for 5 days produced no changes in blood or urine parameters. No injection site irritation was observed following intramuscular injection of the 0.5 mg/lb recommended dose. Some irritation was observed following a 3-fold dose administered intramuscularly.

Cattle: No flunixin-related changes (adverse reactions) were noted in cattle administered a 1X (2.2 mg/kg; 1.0 mg/lb) dose for 9 days (three times the maximum clinical duration). Minimal toxicity manifested itself at moderately elevated doses (3X and 5X) when flunixin was administered daily for 9 days, with occasional findings of blood in the feces and/or urine. Discontinue use if hematuria or fecal blood are observed.

Adverse Reactions:

In horses, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of Banamine Injectable Solution. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.

Caution:

Cattle must not be slaughtered for human consumption within 4 days of the last treatment. Milk that has been taken during treatment and for 36 hours after the last treatment must not be used for food. Not for use in dry dairy cows. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal. Not for use in horses intended for food. Approved only for intravenous administration in cattle. Intramuscular administration has resulted in violative residues in the edible tissues of cattle sent to slaughter.

Storage:

Store between 2° and 30°C (36° and 86°F)

FAQ

BANAMINE Injectable Solution is recommended for the relief of pain in horses, reduce inflammation associated with musculoskeletal disorders and for the alleviation of visceral pain associated with colic in horses. In Cattle, Banamine is used the control of pyrexia (fever) associated with bovine respiratory disease and endotoxemia, and for the control of inflammation in endotoxemia.
Horse & Cattle
Treat pain & lameness in horses - Reduce inflammation caused by musculoskeletal disorders - Fast acting relief for horses and cattle
In horse, isolated reports of local reactions following intramuscular injection, particularly in the neck, have been received. These include localized swelling, sweating, induration, and stiffness. In rare instances in horses, fatal or nonfatal clostridial infections or other infections have been reported in association with intramuscular use of flunixin meglumine. In horses and cattle, rare instances of anaphylactic-like reactions, some of which have been fatal, have been reported, primarily following intravenous use.

Horse: The effect of BANAMINE Injectable Solution on pregnancy has not been determined. Studies to determine activity of BANAMINE Injectable Solution when administered concomitantly with other drugs have not been conducted. Drug compatibility should be monitored closely in patients requiring adjunctive therapy.

Cattle: Do not use in bulls intended for breeding, as reproductive effects of Banamine Injectable Solution in these classes of cattle have not been investigated. NSAIDs are known to have potential effects on both parturition (See Contraindications) and the estrous cycle. There may be a delay in the onset of estrus if flunixin is administered during the prostaglandin phase of the estrous cycle. NSAIDs are known to have the potential to delay parturition through a tocolytic effect. The use of NSAIDs in the immediate post-partum period may interfere with uterine involution and expulsion of fetal membranes. Cows should be monitored carefully for placental retention if Banamine Injectable Solution is used within 24 hours after parturition.

Contact your nearest animal emergency hospital. You may also contact Merck Animal Health Pharmacovigilance: Livestock Technical Services, 800-211-3573
Give the missed dose as soon as you remember. If it is time for the next dose, skip the missed dose and resume a regular dosing schedule.
Avoid concomitant use of Banamine with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids.
Studies to determine the activity of Banamine when administered concomitantly with other drugs have not been conducted.

Customers Who Bought Also Bought